share_log

Is Topchoice Medical Co., Inc.'s (SHSE:600763) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

Is Topchoice Medical Co., Inc.'s (SHSE:600763) Stock's Recent Performance Being Led By Its Attractive Financial Prospects?

是 Topchoice Medical Co., Inc.s (SHSE: 600763) 股票最近的表現是由其誘人的財務前景帶動的?
Simply Wall St ·  04/28 08:12

Most readers would already be aware that Topchoice Medical's (SHSE:600763) stock increased significantly by 14% over the past week. Since the market usually pay for a company's long-term fundamentals, we decided to study the company's key performance indicators to see if they could be influencing the market. In this article, we decided to focus on Topchoice Medical's ROE.

大多數讀者已經意識到,Topchoice Medical(上海證券交易所代碼:600763)的股票在過去一週大幅上漲了14%。由於市場通常會爲公司的長期基本面買單,因此我們決定研究公司的關鍵績效指標,看看它們是否會影響市場。在本文中,我們決定重點介紹Topchoice Medical的投資回報率。

Return on Equity or ROE is a test of how effectively a company is growing its value and managing investors' money. Put another way, it reveals the company's success at turning shareholder investments into profits.

股本回報率或投資回報率是對公司增值和管理投資者資金的有效性的考驗。換句話說,它揭示了公司成功地將股東投資轉化爲利潤。

How To Calculate Return On Equity?

如何計算股本回報率?

ROE can be calculated by using the formula:

ROE 可以通過以下公式計算:

Return on Equity = Net Profit (from continuing operations) ÷ Shareholders' Equity

股本回報率 = 淨利潤(來自持續經營業務)÷ 股東權益

So, based on the above formula, the ROE for Topchoice Medical is:

因此,根據上述公式,Topchoice Medical的投資回報率爲:

13% = CN¥585m ÷ CN¥4.3b (Based on the trailing twelve months to March 2024).

13% = 5.85億元人民幣 ÷ 43億元人民幣(基於截至2024年3月的過去十二個月)。

The 'return' is the profit over the last twelve months. So, this means that for every CN¥1 of its shareholder's investments, the company generates a profit of CN¥0.13.

“回報” 是過去十二個月的利潤。因此,這意味着其股東每投資1元人民幣,公司就會產生0.13CN的利潤。

Why Is ROE Important For Earnings Growth?

爲什麼投資回報率對收益增長很重要?

Thus far, we have learned that ROE measures how efficiently a company is generating its profits. Based on how much of its profits the company chooses to reinvest or "retain", we are then able to evaluate a company's future ability to generate profits. Assuming everything else remains unchanged, the higher the ROE and profit retention, the higher the growth rate of a company compared to companies that don't necessarily bear these characteristics.

到目前爲止,我們已經了解到,投資回報率衡量的是公司創造利潤的效率。根據公司選擇將多少利潤進行再投資或 “保留”,我們便能夠評估公司未來創造利潤的能力。假設其他一切保持不變,那麼與不一定具有這些特徵的公司相比,投資回報率和利潤保留率越高,公司的增長率就越高。

Topchoice Medical's Earnings Growth And 13% ROE

Topchoice Medical的收益增長和13%的投資回報率

At first glance, Topchoice Medical seems to have a decent ROE. Especially when compared to the industry average of 7.0% the company's ROE looks pretty impressive. This probably laid the ground for Topchoice Medical's moderate 6.3% net income growth seen over the past five years.

乍一看,Topchoice Medical的投資回報率似乎不錯。特別是與7.0%的行業平均水平相比,該公司的投資回報率看起來相當可觀。這可能爲Topchoice Medical在過去五年中實現6.3%的溫和淨收入增長奠定了基礎。

As a next step, we compared Topchoice Medical's net income growth with the industry and found that the company has a similar growth figure when compared with the industry average growth rate of 6.7% in the same period.

下一步,我們將Topchoice Medical的淨收入增長與該行業進行了比較,發現與同期6.7%的行業平均增長率相比,該公司的增長數字相似。

past-earnings-growth
SHSE:600763 Past Earnings Growth April 28th 2024
SHSE: 600763 過去的收益增長 2024 年 4 月 28 日

The basis for attaching value to a company is, to a great extent, tied to its earnings growth. The investor should try to establish if the expected growth or decline in earnings, whichever the case may be, is priced in. By doing so, they will have an idea if the stock is headed into clear blue waters or if swampy waters await. One good indicator of expected earnings growth is the P/E ratio which determines the price the market is willing to pay for a stock based on its earnings prospects. So, you may want to check if Topchoice Medical is trading on a high P/E or a low P/E, relative to its industry.

爲公司附加價值的基礎在很大程度上與其收益增長息息相關。無論如何,投資者應設法確定預期的收益增長或下降是否已計入其中。通過這樣做,他們將知道股票是走向清澈的藍色海水還是沼澤水域在等着呢。衡量預期收益增長的一個很好的指標是市盈率,它根據收益前景決定了市場願意爲股票支付的價格。因此,你可能需要檢查一下相對於其行業,Topchoice Medical的交易市盈率是高還是低。

Is Topchoice Medical Making Efficient Use Of Its Profits?

Topchoice Medical是否在有效利用其利潤?

With a three-year median payout ratio of 28% (implying that the company retains 72% of its profits), it seems that Topchoice Medical is reinvesting efficiently in a way that it sees respectable amount growth in its earnings and pays a dividend that's well covered.

Topchoice Medical的三年派息率中位數爲28%(這意味着該公司保留了72%的利潤),看來Topchoice Medical正在進行有效的再投資,其收益將實現可觀的增長,並支付可觀的股息。

Besides, Topchoice Medical has been paying dividends over a period of seven years. This shows that the company is committed to sharing profits with its shareholders.

此外,Topchoice Medical已經在七年內派發了股息。這表明該公司致力於與股東分享利潤。

Conclusion

結論

On the whole, we feel that Topchoice Medical's performance has been quite good. Specifically, we like that the company is reinvesting a huge chunk of its profits at a high rate of return. This of course has caused the company to see substantial growth in its earnings. Having said that, looking at the current analyst estimates, we found that the company's earnings are expected to gain momentum. Are these analysts expectations based on the broad expectations for the industry, or on the company's fundamentals? Click here to be taken to our analyst's forecasts page for the company.

總的來說,我們認爲Topchoice Medical的表現相當不錯。具體而言,我們喜歡該公司以高回報率再投資其利潤的很大一部分。當然,這導致該公司的收益大幅增長。話雖如此,從分析師目前的估計來看,我們發現該公司的收益有望增強。這些分析師的預期是基於對該行業的廣泛預期,還是基於公司的基本面?點擊此處進入我們分析師對公司的預測頁面。

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

對這篇文章有反饋嗎?對內容感到擔憂?直接聯繫我們。 或者,給編輯團隊 (at) simplywallst.com 發送電子郵件。
Simply Wall St的這篇文章本質上是籠統的。我們僅使用公正的方法根據歷史數據和分析師的預測提供評論,我們的文章無意作爲財務建議。它不構成買入或賣出任何股票的建議,也沒有考慮到您的目標或財務狀況。我們的目標是爲您提供由基本數據驅動的長期重點分析。請注意,我們的分析可能不考慮最新的價格敏感型公司公告或定性材料。簡而言之,華爾街沒有持有任何上述股票的頭寸。

譯文內容由第三人軟體翻譯。


以上內容僅用作資訊或教育之目的,不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。
    搶先評論